Openbookopenbook
Equity
Ionis Pharmaceuticals Inc(IONS)
USD --+0.00%
Reward44Moderate
Risk49Moderate
📊75%Data
Thin -40% profit margin · Revenue down 10% YoY
IONS
+0.0 · +0.00%
USD · NASDAQ
Ionis Pharmaceuticals Inc | Healthcare
Earnings Deterioration
Market Cap:13.11Bn
ℹ️
Reward Rating
44
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
49
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on IONS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $92.67.

What is Ionis Pharmaceuticals Inc?

, a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.

IONS · Verdict

Moderate reward · moderate risk

IONS's standout is volatility; cash flow and balance sheet weigh on the picture.

Based on 88% data coverage

IONS · Verdict

What’s working & what to watch

Strengths 1

  • Volatility95/100

    Top decile vs peers

Watchouts 4

  • Cash flow29/100

    -77% free-cash-flow margin

  • Balance sheet30/100

    Current ratio 8.47

  • Profitability32/100

    -64% net margin · -71% ROE

  • Valuation38/100

    P/E 90.9× · PEG 25.70

Model-based scoring. For information only — not financial advice.

What is Ionis Pharmaceuticals Inc?

, a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 13.11B.

Financial Highlights

Investment Breakdown

📈 Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (44)

The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap13.11B
P/E RatioN/A
Dividend YieldN/A
52 Week High86.74
52 Week Low23.95
Last AnnualDecember
IPO Date5/17/1991
IncorporatedUSA
Shares Outstanding162M
No. of Employees1,069
IndustryBiotechnology
ExchangeNASDAQ
Beta0.311
CurrencyUSD
Websitewww.ionis.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.